Norges Bank Acquires Shares of 462,094 Repligen Corporation $RGEN

Norges Bank acquired a new stake in Repligen Corporation (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 462,094 shares of the biotechnology company’s stock, valued at approximately $75,719,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bayforest Capital Ltd bought a new stake in Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC bought a new stake in Repligen in the fourth quarter valued at approximately $33,000. Measured Wealth Private Client Group LLC bought a new stake in Repligen in the third quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares during the period. Finally, Johnson Financial Group Inc. bought a new stake in Repligen in the third quarter valued at approximately $65,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the topic of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Roth Mkm started coverage on Repligen in a research note on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Finally, UBS Group lowered their target price on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $122.31 on Friday. The firm has a market cap of $6.90 billion, a P/E ratio of 135.90, a price-to-earnings-growth ratio of 2.36 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The business’s 50 day moving average is $118.67 and its 200-day moving average is $138.77.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million for the quarter, compared to analyst estimates of $192.05 million. During the same quarter last year, the company earned $0.39 earnings per share. The firm’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts predict that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.